Post by
zootv1 on Jan 20, 2017 6:40pm
OBMP may be EXTREMELY UNDERVALUED
OBMP may be extremely undervalued given the potential for a sub-$100M takeout of its intellectual property assets as the company moves toward further establishing those assets on the $7.1B stage of the prostate cancer treatment market. We would be remiss in our analysis if we additionally failed to note that the stock has a float of under 9.8 million shares. If such a buyout rumor got legs, there is no telling where it might end up.